Synairgen plc

Synairgen plc (www.synairgen.com) is a drug discovery and development company. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The Company is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The Company is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The Company offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.

• Synairgen plc